FDA approves globally first obesity pill
FDA approves Novo Nordisk’s first oral GLP-1 pill Wegovy for obesity, offering an injection-free option and improving long-term treatment adherence.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2213 entries already.
Entries by Thomas Gabrielczyk
Nine Big Pharma to cut US drug prices in Most-favoured Nations deals
Nine pharma giants will cut US drug prices up to 90 % via TrumpRx and direct channels, following previous Pfizer and AstraZeneca MFN deals.
Trump Administration tables new version of Biosecure Act
The Trump administration has tabled a new Biosecure Act, prompting industry concern over oversight shift, regulatory uncertainty and need for stronger US biotech strategy.
EU committee approves New Plant Breeding (NGT) techniques
On Friday, the EU committee of Permanent Representatives of EU Member States backed the deregulation of new genomic plant breeding techniques, easing regulation for NGT1 crops.
Egetis Therapeutics AB submits rolling NDA for tiratricol
Egetis Therapeutics has submitted a rolling NDA for Tiratricol to treat rare MCT8 transporter deficiency. The application for priority review is based on positive ReTRIACt study results.
FoRx raises US$50m in Series A to advance PARG inhibitor
Swiss cancer specialist FoRx Therapeutics AG has secured US$50m Series A to fund Phase I development of FORX-428, supporting IND, trial execution and clinical data readout by mid-2026.
Biopharmaceutical sector welcomes EU Biotech Act
The European Commission has unveiled the first part of its draft for a Biotech Act, focusing on health and medical biotechnology. The proposal has won strong support from industry stakeholders, who say it addresses the urgent need for faster innovation processes to retain and develop biotech in Europe.
Sobi strengthens gout pipeline with Arthrosi acquisition
Sobi AB has completed the US$1.5bn acquisition of Chinese Arthrosi Therapeutics Ltd. Its lead candidate, pozdeutinurad, a URAT1 inhibitor for gout, is in pivotal global Phase-III trials, with China licensing targeting approval by 2028.
Sanofi facing tolebrutinib setback in MS
Sanofi’s tolebrutinib fails Phase III in PPMS, while FDA postpones decision on targeted therapy approval for nrSPMS.
Eifo and Fsg back Fida Biosystems with €5m investment
Fida Biosystems ApS has added €5m from EIFO and FSG to an ongoing Series A financing to scale its Flow-Induced Dispersion Analysis platform, advancing in-solution biophysical analysis for drug discovery.